Back to News
Market Impact: 0.15
Beam Therapeutics Inc. Reports Third Quarter 2026 Financial Results and Clinical Progress
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Beam Therapeutics reported third-quarter 2026 results and ended September 30 with $1.0 billion in cash, cash equivalents and marketable securities, down from $1.2 billion at December 31, 2025. The article text is truncated, so no further results or outlook details are available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.05
Ticker Sentiment
BEAM0.00
More News
- Beam earnings missed by $0.13, revenue fell short of estimates
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?
- Equity Research Automation Statistics: A 2026 Evidence Check